More stories

Psychedelic Bulletin #108 – COMPASS Survives Patent Challenges; MindMed Secures Candyflipping IP; Will Psychedelics...

This Week: Patents: COMPASS Survives Challenges; MindMed Secures Candyflipping IP Will Psychedelics Companies Step Up to Protect Access to Abortions? Colorado’s Initiative 58 Could...

Field Trip Health Ltd. to Present at the H.C. Wainwright 1st Annual Mental Healthcare...

TORONTO, June 23, 2022 (GLOBE NEWSWIRE) — Field Trip Health Ltd. (TSX: FTRP, FTRP.WT, Nasdaq: FTRP) (“Field Trip”), a global leader in the development...

Mindset Pharma and Top Psychiatric Research Hospital, CAMH, Enter Innovative Collaboration to Build Molecular...

TORONTO, June 22, 2022 (GLOBE NEWSWIRE) — Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) (“Mindset” or the “Company”), a drug discovery and...

Yale’s Department of Psychiatry Chair to Join Clearmind Medicine

Dr. John H. Krystal, world-leading expert in alcoholism and depression, will serve on scientific advisory board Source link... Source

CB Therapeutics granted a new patent that will help further provide eco-conscious avenues for...

CARLSBAD, Calif., May 19, 2022 (GLOBE NEWSWIRE) — CB Therapeutics (the “Company”), a biotechnology and precision fermentation company focused on using cellular agriculture to...

Wake Network, Inc. Receives Certificate of Drug Registration for Microdose Formulation in Jamaica

TORONTO, Sept. 23, 2021 /CNW/ – Wake Network, Inc. (“Wake” or the “Company“), a global leader in naturally-derived psilocybin production and the developer of...

Diamond Therapeutics Achieves Last Patient Last Visit in Clinical Trial of Low-Dose Psilocybin

TORONTO, March 29, 2022 /PRNewswire/ – Diamond Therapeutics Inc., a drug development company focused on non-psychedelic doses of psilocybin for use in the treatment...

Gilgamesh Announces Clinical Candidates For Two Programs With First In Human Dosing to Begin...

Novel treatments for depression and other neuropsychiatric disorders NEW YORK, March 24, 2022 /PRNewswire/ — Gilgamesh Pharmaceuticals, a mental health-focused biotechnology company developing novel...

Bexson Biomedical to present at the H.C. Wainwright and Beryl Elites Conferences

SANTA BARBARA, Calif., June 17, 2022 /PRNewswire/ — Bexson Biomedical, Inc., a research-stage company developing therapies and delivery solutions for pain management, addiction and...

Psilera Expands Computational Chemistry Abilities with the Addition of Dr. Daniel N. Santiago

Dr. Santiago will lead the computational chemistry division responsible for the discovery of new therapies for the treatment of CNS disorders. TAMPA, Fla., March...

Danish Synthetic Biology Drug Developer Octarine and British Clinical Research Organisation Clerkenwell Health Partner...

Octarine Bio, the synthetic biology drug development company that produces psilocybin from sugar using fermentation, partners with clinical research organisation Clerkenwell Health to deliver...

HAVN Life To Be Featured On Viewpoint with Dennis Quaid

The Company’s segment will be aired on public television networks across the U.S. starting in July, with interviews featuring CEO Tim Moore and the...

Most popular